Výsledky vyhledávání

Akademický článek

Durable Objective Response to Lurbinectedin in Small Cell Bladder Cancer with TP53 Mutation: A Molecular-Directed Strategy

Autor: Mohammad Jad Moussa, Jaanki Khandelwal, Nathaniel R. Wilson, Sagar A. Naik, Vivek Subbiah, Matthew T. Campbell, Pavlos Msaouel, Parminder Singh, Omar Alhalabi

Publikováno v: Current Oncology, Vol 31, Iss 6, Pp 3342-3349 (2024)

Small cell bladder cancer (SCBC) is a rare and aggressive disease, often treated with platinum/etoposide-based chemotherapy. Key molecular drivers include the inactivation of onco-suppressor genes (TP53, RB1) and amplifications in proto-oncogenes (MY

Externí odkaz: https://doaj.org/article/bbb72ef7a31447418f0648f931ce0d61

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Successful management of pre-existing psoriatic arthritis through targeting the IL-23/IL-17 axis in cancer patients receiving immune checkpoint inhibitor therapy: a case series

Autor: Pavlos Msaouel, Adi Diab, Patrick Hwu, Sang T. Kim, Matthew Campbell, Yuanteng Jeff Li

Publikováno v: RMD Open, Vol 10, Iss 3 (2024)

Background Immune checkpoint inhibitors (ICIs) have significantly improved outcomes for patients with cancer. However, these therapies are associated with adverse events including de novo immune-related adverse events or flare of pre-exiting autoimmu

Externí odkaz: https://doaj.org/article/645c7485a5394d94a0b9d241c919f74f

Zobrazit plný text záznamu

Akademický článek

The IL6/JAK/STAT3 signaling axis is a therapeutic vulnerability in SMARCB1-deficient bladder cancer

Publikováno v: Nature Communications, Vol 15, Iss 1, Pp 1-16 (2024)

Abstract SMARCB1 loss has long been observed in many solid tumors. However, there is a need to elucidate targetable pathways driving growth and metastasis in SMARCB1-deficient tumors. Here, we demonstrate that SMARCB1 deficiency, defined as genomic S

Externí odkaz: https://doaj.org/article/92dacc4a9b18472087b40b7343faadf4

Zobrazit plný text záznamu

Akademický článek

Postprogression therapy and confounding for the estimated treatment effect on overall survival in phase III oncology trials

Autor: Pavlos Msaouel, Ramez Kouzy, Joseph Abi Jaoude, Ethan B Ludmir, Alexander D Sherry, Timothy A Lin, Esther J Beck, Avital M Miller, Adina H Passy, Gabrielle S Kupferman, Eugene J Koay, Clifton David Fuller, Charles R Thomas, Zachary R McCaw

Publikováno v: BMJ Oncology, Vol 3, Iss 1 (2024)

Objective Estimations of the treatment effect on overall survival (OS) may be influenced by post-progression therapies (PPTs). It is unclear how often OS analyses account for PPT effects. The purpose of this cross-sectional analysis was to determine

Externí odkaz: https://doaj.org/article/284718e1663b466c99a570c4fdc80d03

Zobrazit plný text záznamu

Akademický článek

Müllerian-Type Clear Cell Carcinoma of Donor Origin in a Male Patient with a Kidney Transplant: Ascertained by Molecular Testing

Autor: J. Bryan Iorgulescu, Leah K. Shaw, Asif Rashid, Priya Rao, Sreedhar Mandayam, Keyur P. Patel, Kathleen M. Schmeler, Richard K. Yang, Pavlos Msaouel

Publikováno v: Current Oncology, Vol 30, Iss 10, Pp 9019-9027 (2023)

Clear cell carcinomas of Müllerian origin have a strong female predominance and only extremely rarely will arise within the kidney, presumably due to ectopic Müllerian embryogenesis. Herein, we report a unique case of metastatic Müllerian type cle

Externí odkaz: https://doaj.org/article/d574c19ba193436980ddfb595b27cbbc

Zobrazit plný text záznamu

Plný text ve formátu HTML